HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

HIGHTIDE-B

3.040

0.000

Volume:260.00K

Turnover:784.01K

Market Cap:1.74B

PE:-3.29

High:3.080

Open:3.000

Low:2.910

Close:3.040

52wk High:4.700

52wk Low:0.870

Shares:571.00M

HK Float Shares:571.00M

Volume Ratio:0.74

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.925

ROE:-62.13%

ROA:-35.29%

PB:5.02

PE(LYR):-3.29

PS:46.32

Loading ...

Overview Company News Filings

HighTide Therapeutics (2511) Announces HTD1801 Renal Benefit Findings at ASN 2025

Bulletin Express

2025 ASN Breakthrough Session: HIGHTIDE-B (02511) Presents Renal Benefits Data for HTD1801

HighTide Therapeutics Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting

HighTide Therapeutics, Inc. (02511) Reports No Changes in Share Capital for October 2025

Bulletin Express

HighTide Therapeutics (2511) Announces Positive 52-Week Results from Phase III Trials of HTD1801 for Type 2 Diabetes

Bulletin Express

HIGHTIDE-B (02511): Global First-in-Class Anti-Inflammatory Metabolic Modulator HTD1801 Completes Phase III Study for Type 2 Diabetes, Demonstrating Sustained 52-Week Benefits and Safety Advantages

HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes

Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%

Tiger Newspress

HighTide Therapeutics Narrows H1 Loss; Shares Rise 7%

MT Newswires Live

BRIEF-Hightide Therapeutics Posts HY Loss Attributable Of RMB120.3 Mln

HIGHTIDE-B (02511) Reports Interim Results with Shareholders' Loss of RMB 120 Million, Narrowing 42.96% Year-over-Year

HighTide Therapeutics Inc - Hy Loss Attributable RMB120.3 Mln

THOMSON REUTERS

HighTide Unit Launches Diabetes-Kidney Drug Study with Chinese Academy; Shares Rise 2%

MT Newswires Live

BRIEF-Hightide Therapeutics Says Unit Commenced Collaborative Project

HighTide Therapeutics Inc - Unit Commenced Collaborative Project With Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

THOMSON REUTERS

HighTide Therapeutics Inc - Project to Explore Metabolic and Renal Benefits- Potential of Innovative Drugs

THOMSON REUTERS

HighTide Therapeutics Completes Successful Placement of 56.55 Million New Shares at HK$2.21 Each

Hightide Therapeutics Inc. Conducted Annual General Meeting

BRIEF-Hightide Therapeutics Inc To Place Up To 60.0 Million Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02511/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02511","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02511\",,,,,undefined,":{"symbol":"02511","market":"HK","secType":"STK","nameCN":"HIGHTIDE-B","latestPrice":3.04,"timestamp":1763096944922,"preClose":3.04,"halted":0,"volume":260000,"delay":0,"floatShares":571000000,"shares":571000000,"eps":-0.9250267118317499,"marketStatus":"Trading","change":0,"latestTime":"11-14 13:09:18","open":3,"high":3.08,"low":2.91,"amount":784010,"amplitude":0.055921,"askPrice":3.07,"askSize":2000,"bidPrice":3.03,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":-0.7053794192272732,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763107800000},"marketStatusCode":2,"adr":0,"listingDate":1703174400000,"exchange":"SEHK","adjPreClose":3.04,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":0.742626,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02511\",,,,,undefined,":{"symbol":"02511","floatShares":571000000,"roa":"-35.29%","roe":"-62.13%","lyrEps":-0.925027,"volumeRatio":0.742626,"shares":571000000,"dividePrice":0,"high":3.08,"amplitude":0.055921,"preClose":3.04,"low":2.91,"week52Low":0.87,"pbRate":"5.02","psRate":"46.32","week52High":4.7,"institutionHeld":0,"latestPrice":3.04,"committee":0.846154,"eps":-0.9250267118317499,"divideRate":0,"volume":260000,"delay":0,"ttmEps":-0.7053794192272732,"open":3,"prevYearClose":1.27,"prevWeekClose":3.23,"prevMonthClose":3.74,"prevQuarterClose":3.84,"fiveDayClose":3.23,"twentyDayClose":3.3,"sixtyDayClose":3.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02511\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02511","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post Market","dateTimestamp":1743091200000,"actualEps":null},{"market":"HK","date":"2024-08-28","symbol":"02511","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724774400000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-27","symbol":"02511","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711503000000,"name":null,"time":"","dateTimestamp":1711468800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02511\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02511\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02511\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02511","date":"2025-11-12","current":-4.310755,"percent":0.236559,"low":-9.095359,"twenty":-6.052653,"median":-2.474519,"eighty":-0.860191,"high":-0.503695,"avg":-3.2513,"sd":2.638662,"marketCap":1708263747},"quantilePoints":[{"date":"2023-12-22","current":-8.734639,"twenty":-8.492642,"median":-8.129647,"eighty":-8.127643,"marketCap":6372860869},{"date":"2023-12-29","current":-9.095359,"twenty":-8.98365,"median":-8.695581,"eighty":-8.129647,"marketCap":6671427857},{"date":"2024-01-05","current":-8.537988,"twenty":-8.784441,"median":-8.544038,"eighty":-8.248369,"marketCap":6218429669},{"date":"2024-01-12","current":-8.363907,"twenty":-8.685299,"median":-8.537988,"eighty":-8.346736,"marketCap":6094884709},{"date":"2024-01-19","current":-8.1349,"twenty":-8.659812,"median":-8.456167,"eighty":-8.207816,"marketCap":5919862682},{"date":"2024-01-26","current":-8.649584,"twenty":-8.650972,"median":-8.460912,"eighty":-8.207816,"marketCap":6269906736},{"date":"2024-02-02","current":-8.361984,"twenty":-8.650972,"median":-8.483943,"eighty":-8.264989,"marketCap":6053703055},{"date":"2024-02-09","current":-8.504973,"twenty":-8.597346,"median":-8.473421,"eighty":-8.275661,"marketCap":6187543429},{"date":"2024-02-16","current":-8.602173,"twenty":-8.63062,"median":-8.476958,"eighty":-8.294295,"marketCap":6259611322},{"date":"2024-02-23","current":-8.036159,"twenty":-8.595019,"median":-8.473421,"eighty":-8.208635,"marketCap":5816908548},{"date":"2024-03-01","current":-7.945863,"twenty":-8.576687,"median":-8.451284,"eighty":-8.127643,"marketCap":5755136068},{"date":"2024-03-08","current":-6.052653,"twenty":-8.560192,"median":-8.40877,"eighty":-7.978802,"marketCap":4385846091},{"date":"2024-03-15","current":-5.695388,"twenty":-8.551566,"median":-8.362945,"eighty":-7.867218,"marketCap":4123313050},{"date":"2024-03-22","current":-4.312815,"twenty":-8.548208,"median":-8.27805,"eighty":-6.066123,"marketCap":3119510248},{"date":"2024-03-28","current":-2.992001,"twenty":-8.543906,"median":-8.212744,"eighty":-5.745595,"marketCap":3042294647},{"date":"2024-04-05","current":-2.73463,"twenty":-8.539468,"median":-8.197001,"eighty":-5.576119,"marketCap":2779761607},{"date":"2024-04-12","current":-2.176341,"twenty":-8.534781,"median":-8.129647,"eighty":-4.493311,"marketCap":2213513872},{"date":"2024-04-19","current":-2.517594,"twenty":-8.523109,"median":-8.043912,"eighty":-4.309916,"marketCap":2558410219},{"date":"2024-04-26","current":-2.586635,"twenty":-8.508057,"median":-7.951497,"eighty":-2.864821,"marketCap":2625330406},{"date":"2024-05-03","current":-2.649329,"twenty":-8.498668,"median":-7.924262,"eighty":-2.751198,"marketCap":2687102886},{"date":"2024-05-10","current":-3.422806,"twenty":-8.484817,"median":-7.769212,"eighty":-2.737043,"marketCap":3479849715},{"date":"2024-05-17","current":-3.275714,"twenty":-8.477244,"median":-6.276091,"eighty":-2.747016,"marketCap":3325418515},{"date":"2024-05-24","current":-2.698739,"twenty":-8.474688,"median":-5.875073,"eighty":-2.745416,"marketCap":2733432247},{"date":"2024-05-31","current":-2.594452,"twenty":-8.468417,"median":-5.713034,"eighty":-2.710462,"marketCap":2630478113},{"date":"2024-06-07","current":-2.277412,"twenty":-8.457116,"median":-5.462224,"eighty":-2.655805,"marketCap":2306172592},{"date":"2024-06-14","current":-2.08615,"twenty":-8.451368,"median":-5.115854,"eighty":-2.588198,"marketCap":2110559738},{"date":"2024-06-21","current":-1.830485,"twenty":-8.444904,"median":-4.331734,"eighty":-2.536299,"marketCap":1848026698},{"date":"2024-06-28","current":-0.719236,"twenty":-8.417702,"median":-4.312815,"eighty":-2.477957,"marketCap":725826641},{"date":"2024-07-05","current":-0.596943,"twenty":-8.40877,"median":-4.051691,"eighty":-2.463651,"marketCap":602281681},{"date":"2024-07-12","current":-0.636823,"twenty":-8.366276,"median":-3.549353,"eighty":-2.277412,"marketCap":643463335},{"date":"2024-07-19","current":-0.560394,"twenty":-8.363907,"median":-3.496298,"eighty":-2.190964,"marketCap":566247734},{"date":"2024-07-26","current":-0.517715,"twenty":-8.361984,"median":-3.220684,"eighty":-2.08615,"marketCap":525066081},{"date":"2024-08-02","current":-0.75671,"twenty":-8.318662,"median":-2.992001,"eighty":-1.873562,"marketCap":767008295},{"date":"2024-08-09","current":-0.776926,"twenty":-8.27805,"median":-2.863181,"eighty":-0.894876,"marketCap":792746828},{"date":"2024-08-16","current":-0.766537,"twenty":-8.266106,"median":-2.770601,"eighty":-0.773016,"marketCap":782451415},{"date":"2024-08-23","current":-0.652832,"twenty":-8.212744,"median":-2.747107,"eighty":-0.75671,"marketCap":669201868},{"date":"2024-08-30","current":-1.100172,"twenty":-8.205896,"median":-2.728047,"eighty":-0.729206,"marketCap":725826641},{"date":"2024-09-06","current":-0.912468,"twenty":-8.188106,"median":-2.679629,"eighty":-0.740924,"marketCap":602281681},{"date":"2024-09-13","current":-0.656825,"twenty":-8.1349,"median":-2.649329,"eighty":-0.723174,"marketCap":432407361},{"date":"2024-09-20","current":-0.691774,"twenty":-8.130698,"median":-2.594452,"eighty":-0.718911,"marketCap":458145894},{"date":"2024-09-27","current":-0.788079,"twenty":-8.126975,"median":-2.574831,"eighty":-0.711909,"marketCap":525066081},{"date":"2024-10-04","current":-0.892575,"twenty":-8.081521,"median":-2.538273,"eighty":-0.714203,"marketCap":591986268},{"date":"2024-10-10","current":-0.882415,"twenty":-8.045462,"median":-2.524212,"eighty":-0.716377,"marketCap":581690854},{"date":"2024-10-18","current":-0.879542,"twenty":-8.029599,"median":-2.476753,"eighty":-0.71826,"marketCap":576543148},{"date":"2024-10-25","current":-0.879598,"twenty":-7.992455,"median":-2.46526,"eighty":-0.719628,"marketCap":576543148},{"date":"2024-11-01","current":-0.933943,"twenty":-7.949243,"median":-2.40723,"eighty":-0.720238,"marketCap":612577094},{"date":"2024-11-08","current":-0.972706,"twenty":-7.937223,"median":-2.272633,"eighty":-0.721432,"marketCap":633167921},{"date":"2024-11-15","current":-0.836682,"twenty":-7.912537,"median":-2.191611,"eighty":-0.725587,"marketCap":540509201},{"date":"2024-11-22","current":-0.837164,"twenty":-7.876462,"median":-2.165315,"eighty":-0.733893,"marketCap":540509201},{"date":"2024-11-29","current":-0.781798,"twenty":-7.785116,"median":-2.08615,"eighty":-0.746636,"marketCap":504475254},{"date":"2024-12-06","current":-0.799637,"twenty":-7.200158,"median":-1.899521,"eighty":-0.755806,"marketCap":514770668},{"date":"2024-12-13","current":-0.768352,"twenty":-6.314044,"median":-1.830485,"eighty":-0.757354,"marketCap":494179841},{"date":"2024-12-20","current":-0.917454,"twenty":-6.072858,"median":-1.096301,"eighty":-0.757354,"marketCap":586838561},{"date":"2024-12-27","current":-1.047032,"twenty":-6.052653,"median":-1.059897,"eighty":-0.758321,"marketCap":669201868},{"date":"2025-01-03","current":-0.89313,"twenty":-5.910589,"median":-1.030203,"eighty":-0.759127,"marketCap":571395441},{"date":"2025-01-10","current":-0.872296,"twenty":-5.819219,"median":-1.016579,"eighty":-0.765095,"marketCap":555952321},{"date":"2025-01-17","current":-0.928085,"twenty":-5.745595,"median":-0.982343,"eighty":-0.767989,"marketCap":591986268},{"date":"2025-01-24","current":-0.890226,"twenty":-5.702446,"median":-0.971737,"eighty":-0.768352,"marketCap":571395441},{"date":"2025-01-28","current":-0.909941,"twenty":-5.677229,"median":-0.965955,"eighty":-0.76868,"marketCap":586838561},{"date":"2025-02-07","current":-0.962836,"twenty":-5.576119,"median":-0.960006,"eighty":-0.770428,"marketCap":617724801},{"date":"2025-02-14","current":-0.916884,"twenty":-5.437951,"median":-0.957687,"eighty":-0.772342,"marketCap":586838561},{"date":"2025-02-21","current":-1.079861,"twenty":-5.295856,"median":-0.96114,"eighty":-0.773201,"marketCap":694940401},{"date":"2025-02-28","current":-0.922924,"twenty":-4.99937,"median":-0.960573,"eighty":-0.77414,"marketCap":591986268},{"date":"2025-03-07","current":-0.807326,"twenty":-4.493311,"median":-0.957265,"eighty":-0.775085,"marketCap":519918374},{"date":"2025-03-14","current":-0.966841,"twenty":-4.332382,"median":-0.951297,"eighty":-0.775904,"marketCap":622872508},{"date":"2025-03-21","current":-1.151073,"twenty":-4.329727,"median":-0.958109,"eighty":-0.776927,"marketCap":741269761},{"date":"2025-03-28","current":-1.305593,"twenty":-4.323383,"median":-0.961988,"eighty":-0.77695,"marketCap":839076188},{"date":"2025-04-03","current":-1.964669,"twenty":-4.312815,"median":-0.968609,"eighty":-0.77703,"marketCap":803042242},{"date":"2025-04-11","current":-1.804502,"twenty":-4.298321,"median":-0.972706,"eighty":-0.779537,"marketCap":730974348},{"date":"2025-04-17","current":-2.094006,"twenty":-4.101017,"median":-0.982343,"eighty":-0.781346,"marketCap":849371602},{"date":"2025-04-25","current":-2.153289,"twenty":-3.838494,"median":-0.984395,"eighty":-0.781962,"marketCap":875110135},{"date":"2025-05-02","current":-2.275118,"twenty":-3.638788,"median":-0.998444,"eighty":-0.782191,"marketCap":926587202},{"date":"2025-05-09","current":-3.363784,"twenty":-3.551198,"median":-1.021661,"eighty":-0.782445,"marketCap":1379585390},{"date":"2025-05-16","current":-3.99636,"twenty":-3.977419,"median":-1.026921,"eighty":-0.783805,"marketCap":1652413844},{"date":"2025-05-23","current":-3.475525,"twenty":-3.891419,"median":-1.043315,"eighty":-0.788891,"marketCap":1441357870},{"date":"2025-05-30","current":-2.595234,"twenty":-3.819658,"median":-1.05978,"eighty":-0.79364,"marketCap":1081018402},{"date":"2025-06-06","current":-3.217297,"twenty":-3.690833,"median":-1.079861,"eighty":-0.799918,"marketCap":1343551443},{"date":"2025-06-13","current":-3.979986,"twenty":-3.819658,"median":-1.125622,"eighty":-0.801093,"marketCap":1662709257},{"date":"2025-06-20","current":-3.555688,"twenty":-3.891829,"median":-1.260849,"eighty":-0.802505,"marketCap":1482539523},{"date":"2025-06-27","current":-3.398018,"twenty":-3.858555,"median":-1.338636,"eighty":-0.807993,"marketCap":1420767043},{"date":"2025-07-04","current":-3.348614,"twenty":-3.850482,"median":-1.395853,"eighty":-0.810663,"marketCap":1400176216},{"date":"2025-07-11","current":-4.33787,"twenty":-3.901653,"median":-1.565723,"eighty":-0.818449,"marketCap":1811992751},{"date":"2025-07-18","current":-4.941417,"twenty":-4.032449,"median":-1.709388,"eighty":-0.827717,"marketCap":2062485661},{"date":"2025-07-25","current":-4.84168,"twenty":-4.072278,"median":-1.830485,"eighty":-0.829191,"marketCap":2028206121},{"date":"2025-08-01","current":-4.226787,"twenty":-4.272195,"median":-1.888937,"eighty":-0.829739,"marketCap":1759683057},{"date":"2025-08-08","current":-4.394198,"twenty":-4.326025,"median":-1.964669,"eighty":-0.830438,"marketCap":1833955394},{"date":"2025-08-15","current":-4.551598,"twenty":-4.330653,"median":-2.021536,"eighty":-0.833182,"marketCap":1896801217},{"date":"2025-08-22","current":-4.428389,"twenty":-4.337848,"median":-2.077326,"eighty":-0.833612,"marketCap":1839668650},{"date":"2025-08-29","current":-6.120211,"twenty":-4.380509,"median":-2.09259,"eighty":-0.836682,"marketCap":1948220527},{"date":"2025-09-05","current":-6.359835,"twenty":-4.480886,"median":-2.122167,"eighty":-0.837164,"marketCap":2022492864},{"date":"2025-09-12","current":-7.854809,"twenty":-4.551598,"median":-2.149237,"eighty":-0.837164,"marketCap":2502406425},{"date":"2025-09-19","current":-7.860387,"twenty":-4.786316,"median":-2.153472,"eighty":-0.838292,"marketCap":2502406425},{"date":"2025-09-26","current":-7.017182,"twenty":-4.941417,"median":-2.183652,"eighty":-0.84547,"marketCap":2228170105},{"date":"2025-10-03","current":-7.036374,"twenty":-5.00868,"median":-2.202955,"eighty":-0.847167,"marketCap":2239596618},{"date":"2025-10-10","current":-6.399502,"twenty":-5.389404,"median":-2.271485,"eighty":-0.847613,"marketCap":2033919378},{"date":"2025-10-17","current":-6.134636,"twenty":-5.76051,"median":-2.316794,"eighty":-0.84775,"marketCap":1948220527},{"date":"2025-10-24","current":-6.635946,"twenty":-5.949231,"median":-2.385869,"eighty":-0.85134,"marketCap":2108191714},{"date":"2025-10-31","current":-6.715847,"twenty":-6.05096,"median":-2.429559,"eighty":-0.85508,"marketCap":2136757998},{"date":"2025-11-07","current":-5.803675,"twenty":-6.064964,"median":-2.466868,"eighty":-0.858385,"marketCap":1845381907},{"date":"2025-11-12","current":-5.372342,"twenty":-6.052653,"median":-2.474519,"eighty":-0.860191,"marketCap":1708263747}],"updateTime":1763071324432},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02511\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183910975","title":"HighTide Therapeutics (2511) Announces HTD1801 Renal Benefit Findings at ASN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1183910975","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183910975?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:21","pubTimestamp":1762474865,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (2511) presented data at the 58th Annual Meeting of the American Society of Nephrology (ASN) in Houston, highlighting a potential renal benefit of HTD1801 in patients with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1120646221","title":"2025 ASN Breakthrough Session: HIGHTIDE-B (02511) Presents Renal Benefits Data for HTD1801","url":"https://stock-news.laohu8.com/highlight/detail?id=1120646221","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120646221?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:12","pubTimestamp":1762474334,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced that it showcased renal benefits data for HTD1801 in patients with mild renal impairment at the 58th American Society of Nephrology (ASN) Annual Meeting in Houston, USA....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2581031042","title":"HighTide Therapeutics Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581031042","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581031042?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:07","pubTimestamp":1762474074,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. has announced the presentation of new clinical evidence demonstrating the potential renal benefits of its lead asset, HTD1801, in patients with mild renal impairment. The results were presented at the 58th Annual Meeting of the American Society of Nephrology  in Houston, US. HTD1801 is described as a first-in-class anti-inflammatory metabolic modulator with dual mechanisms of AMPK activation and NLRP3 inhibition, aimed at addressing residual risks associated with cardiovascular-kidney-metabolic diseases. Data supporting these findings were derived from two randomized, double-blind, placebo-controlled Phase III studies. The company notes that HTD1801 has received two Fast Track designations and one Orphan Drug designation from the US FDA. HighTide Therapeutics cautions that there is no guarantee HTD1801 will ultimately be successfully marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL3VGjwp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"1162974853","title":"HighTide Therapeutics, Inc. (02511) Reports No Changes in Share Capital for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1162974853","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162974853?lang=en_us&edition=fundamental","pubTime":"2025-11-04 17:04","pubTimestamp":1762247088,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 02511) submitted a monthly return announcing that, as of October 31, 2025, total authorized share capital stood at US$100,000, with 1,000,000,000 ordinary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1199086183","title":"HighTide Therapeutics (2511) Announces Positive 52-Week Results from Phase III Trials of HTD1801 for Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=1199086183","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199086183?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:24","pubTimestamp":1761870283,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 2511) released 52-week data from two Phase III clinical trials, SYMPHONY-1 and SYMPHONY-2, evaluating its new molecular entity HTD1801 in adult patients with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1133422433","title":"HIGHTIDE-B (02511): Global First-in-Class Anti-Inflammatory Metabolic Modulator HTD1801 Completes Phase III Study for Type 2 Diabetes, Demonstrating Sustained 52-Week Benefits and Safety Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=1133422433","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133422433?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:06","pubTimestamp":1761869172,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced the successful completion of two Phase III clinical trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes (T2DM). The 52-week study,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","BK1161","02511"],"gpt_icon":0},{"id":"2579107493","title":"HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579107493?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:06","pubTimestamp":1761869164,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.Disclaimer: This news brief was created by Public Technologies  using generative arti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1zytV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"1165477251","title":"Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165477251","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165477251?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:48","pubTimestamp":1757641711,"startTime":"0","endTime":"0","summary":"Biotech stocks rebounded on Friday. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"dbb90568ab4fea5a8074bebd42fd3ce0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","02197","02511","09966","09688","02617"],"gpt_icon":0},{"id":"2562783929","title":"HighTide Therapeutics Narrows H1 Loss; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562783929","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562783929?lang=en_us&edition=fundamental","pubTime":"2025-08-26 15:49","pubTimestamp":1756194553,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics  booked a loss attributable to owners of 120.3 million yuan for the first half of 2025, compared with a loss of 211 million yuan a year earlier, according to a Monday Hong Kong bourse filing.Shares of the biopharmaceutical firm gained over 7% in Tuesday late-afternoon trade.Loss per share came in at 0.27 yuan, compared with 0.47 yuan in the prior-year period.The company said that no revenue was derived during the six months ended June 30.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02511","BK4007","LENZ","BK4539","BK4139","BK1161"],"gpt_icon":0},{"id":"2562243436","title":"BRIEF-Hightide Therapeutics Posts HY Loss Attributable Of RMB120.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562243436","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562243436?lang=en_us&edition=fundamental","pubTime":"2025-08-25 18:49","pubTimestamp":1756118973,"startTime":"0","endTime":"0","summary":"BRIEF-Hightide Therapeutics Posts HY Loss Attributable Of RMB120.3 MlnAug 25 (Reuters) - HighTide Therapeutics Inc 2511.HK:HY LOSS ATTRIBUTABLE RMB120.3 MILLIONFurther company coverage: 2511.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UF01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"1155355540","title":"HIGHTIDE-B (02511) Reports Interim Results with Shareholders' Loss of RMB 120 Million, Narrowing 42.96% Year-over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1155355540","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155355540?lang=en_us&edition=fundamental","pubTime":"2025-08-25 16:38","pubTimestamp":1756111103,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced its interim results for the six months ended June 30, 2025. The company reported other income of RMB 10.542 million, representing a decrease of 69.96% compared to the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2562211462","title":"HighTide Therapeutics Inc - Hy Loss Attributable RMB120.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562211462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562211462?lang=en_us&edition=fundamental","pubTime":"2025-08-25 16:31","pubTimestamp":1756110681,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UF01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02511"],"gpt_icon":0},{"id":"2559424608","title":"HighTide Unit Launches Diabetes-Kidney Drug Study with Chinese Academy; Shares Rise 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559424608","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559424608?lang=en_us&edition=fundamental","pubTime":"2025-08-13 17:05","pubTimestamp":1755075944,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics  said its wholly owned subsidiary, Shenzhen HighTide Biopharmaceutical, has launched a research collaboration with the Institute of Medicinal Biotechnology under the Chinese Academy of Medical Sciences, according to a Tuesday Hong Kong bourse filing.The project will study the company's lead drug candidate, HTD1801, for type 2 diabetes with chronic kidney disease.Shares of HighTide gained 2% in Wednesday late-afternoon trade.The collaboration will assess HTD1801's multi-indication potential, targeting improvements in blood glucose, kidney and liver function, lipids, cardiovascular health, body weight, and inflammation.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02511"],"gpt_icon":0},{"id":"2558628909","title":"BRIEF-Hightide Therapeutics Says Unit Commenced Collaborative Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2558628909","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558628909?lang=en_us&edition=fundamental","pubTime":"2025-08-12 23:16","pubTimestamp":1755011795,"startTime":"0","endTime":"0","summary":"BRIEF-Hightide Therapeutics Says Unit Commenced Collaborative ProjectAug 12  - HighTide Therapeutics Inc 2511.HK:UNIT COMMENCED COLLABORATIVE PROJECT WITH INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESPROJECT TO EXPLORE METABOLIC AND RENAL BENEFITS- POTENTIAL OF INNOVATIVE DRUGSFurther company coverage: 2511.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nFWN3U40AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2558496386","title":"HighTide Therapeutics Inc - Unit Commenced Collaborative Project With Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2558496386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558496386?lang=en_us&edition=fundamental","pubTime":"2025-08-12 18:56","pubTimestamp":1754996178,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nFWN3U40AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2558493736","title":"HighTide Therapeutics Inc - Project to Explore Metabolic and Renal Benefits- Potential of Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2558493736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558493736?lang=en_us&edition=fundamental","pubTime":"2025-08-12 18:56","pubTimestamp":1754996178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nFWN3U40AO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2549753835","title":"HighTide Therapeutics Completes Successful Placement of 56.55 Million New Shares at HK$2.21 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2549753835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549753835?lang=en_us&edition=fundamental","pubTime":"2025-07-07 17:47","pubTimestamp":1751881633,"startTime":"0","endTime":"0","summary":"Hightide Therapeutics Inc., a company incorporated in the Cayman Islands, announced the successful completion of a private placement of new shares under a general mandate. A total of 56,555,000 new shares were placed by the Placing Agents to at least six independent placees at a price of HK$2.21 per share. This move effectively enlarges the company's share capital. Dr. Liu Liping, the Executive Director and CEO, confirmed that all conditions of the Placing Agreement were fulfilled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDLbJLx9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"2546745892","title":"Hightide Therapeutics Inc. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546745892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546745892?lang=en_us&edition=fundamental","pubTime":"2025-06-27 20:17","pubTimestamp":1751026648,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. held its Annual General Meeting on June 27, 2025. During the meeting, several proposals were put forward and voted upon. All proposals were approved as ordinary resolutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL55kkGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2546737392","title":"BRIEF-Hightide Therapeutics Inc To Place Up To 60.0 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2546737392","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546737392?lang=en_us&edition=fundamental","pubTime":"2025-06-26 09:46","pubTimestamp":1750902386,"startTime":"0","endTime":"0","summary":"BRIEF-Hightide Therapeutics Inc To Place Up To 60.0 Million SharesJune 26 (Reuters) - HighTide Therapeutics Inc 2511.HK:TO PLACE UP TO 60.0 MILLION SHARES AT HK$2.21 PER SHAREFurther company coverage: 2511.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}